Zogenix, Inc. Begins Relday™ Clinical Trial for Schizophrenia

SAN DIEGO, July 12, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has initiated its first IND clinical trial for Relday™, a product candidate based on a combination of its DosePro® needle-free, subcutaneous drug delivery system with a proprietary, subcutaneous once-monthly formulation of risperidone for treating schizophrenia. The Phase 1 clinical trial for Relday is a single-center, open-label, safety and pharmacokinetic (PK) trial that will enroll 30 patients with chronic, stable schizophrenia or schizoaffective disorder. Zogenix expects that study results will be available by the end of 2012. Further study information can be found at http://www.clinicaltrials.gov and reference NCT01592110.